ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

WPCT Woodford Patient Capital Trust Plc

33.60
0.00 (0.00%)
18 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Woodford Patient Capital Trust Plc LSE:WPCT London Ordinary Share GB00BVG1CF25 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 33.60 33.55 33.90 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Woodford Patient Capital Share Discussion Threads

Showing 701 to 718 of 11725 messages
Chat Pages: Latest  37  36  35  34  33  32  31  30  29  28  27  26  Older
DateSubjectAuthorDiscuss
18/2/2016
19:44
if it was a concentrated portfolio i would be concerned.
it's not.

as for bio, a major shakeout is called for just as it was in internet stocks a few years back, then look what happened a few years later.

p1nkfish
18/2/2016
16:17
you can spreadbet WPTC long or short!
toffeeman
18/2/2016
14:21
LK, why so vociferous in your posts.

I happen to think the biotech bubble is bursting and there is further
downside for valuations, how that precisely impacts WPCT remains to be seen.

However my caution could be incorrect, none of us know the future
and some invest with a very long term view.

There are probably ways to short the sector if you are so convinced in your
outlook.

essentialinvestor
18/2/2016
14:15
There's still a herd of sheeple mustering to get into Biotech - to lock the inheritance away for eternity?

January's 10 most-bought trusts
Rank Name AIC sector 1m share price return to 4 Feb (%)
1 Scottish Mortgage Global -10.7
2 Woodford Patient Cap UK all cos -9.9
4 Biotech Growth trust Biot & healthcare -15.2

liquidkid
18/2/2016
12:30
agree p1nkfish, this is very much a lock and put away portfolio. to be honest, I have always assumed that the real growth will come in the unquoted investments and the returns will be very lumpy as some will come to nought and others will be multi-baggers. on the other hand, it is nice to notice how the trolls will scream and shout when an investment goes down (such as when PURP was floated at £1 and sank to 80p), but go silent when they go up (such as when PURP bounced back from 80p to today's price north of 130p).
mad foetus
18/2/2016
10:29
Oh dear, wee willie the kid has given up any pretence of being rational.
the air marshall
17/2/2016
23:27
Not healthy to keep looking at the individual portfolio stock performances. Set and forget (some call it patience) is better for the mind so long as the portfolio is large, relatively diverse and weighted to cope with the risk. It is all those things.
p1nkfish
17/2/2016
16:26
Prothena and NWBO both up 8% atm today
mad foetus
17/2/2016
16:02
E-therapeutics makes up 0.11% of the WEIF. Its not in WPCT. There are 150 or so different stocks and some are going to go sour (particularly on here).

Companies like that are risky and its why they are small holdings. I am comfortable with that. If you don't like it then perhaps you should put it in NSI

dr biotech
17/2/2016
12:51
Please leave LK alone, it's half term and raining outside, what else is he to do.
prewar
17/2/2016
11:31
Hee Hee.

Very good, TAM.

pete_bane
17/2/2016
11:25
Liquescent Kid. All your silly and hysterical fulminations are not having any effect, are they? The share is beginning to rise again, possibly to continue.

It's the market, stupid!

the air marshall
17/2/2016
09:08
Don't want to have to put out another downer, but you just can't ignore that this is happening on a inexcusable level of regularity.

And now for the Clanger of the week:

Oxford-based e-Therapeutics' (ETX) most advanced drug flopped badly in a Phase IIb study for depression, beaten out on efficacy by an aging generic generiatric.

Is The latest in a long lineup of companies to try a new strategy in combating depression and fail at it. Alkermes (ALKS) recently attempted its own pivotal study using a new study design that randomized nonresponders in the initial placebo group only to concede failure just weeks ago.

This observation sums it up nicely
Mach100 15 Feb'16 (ETX)
Not an investor here but have seen a few presentations at Mayfair. They looked interesting at that time. Today's RNS seems weird to me. It seemed to be presented as good news when it is probably anything but. A massive drop first thing and any bottom feeders would have done well. I can't see given the wooliness of the RNS any great upside on this so I confess I am slightly bemused by the share price partial recovery since the opening.

- The share price movement has all the hallmarks of Woofordunnit Meddling.

liquidkid
11/2/2016
18:57
5m trade showing at the close?!
toffeeman
11/2/2016
18:51
The issue here is the price, which is over generously priced.

Woodford don't get everything right nor does he get all the timing right. However, he did get something right, that is his totally avoiding mining, oil&gas and financials.

If this was priced in 60 to 70 range, I would put some money here.

ceaserxzy
11/2/2016
17:39
I like his WEIF but there are definite questions here......
chinahere
09/2/2016
19:29
I make it 41.05% unquoted companies using the full list on the Woodford website.
chinahere
09/2/2016
19:02
Jonwig, I agree that there is no point to revalue it daily nor will it be economical. What I imply is that we PI need to bear this in mind when making an investment decision. So for this to be attractive priced, it has to be at a reasonable discount, not at a premium as it currently stands.
ceaserxzy
Chat Pages: Latest  37  36  35  34  33  32  31  30  29  28  27  26  Older

Your Recent History

Delayed Upgrade Clock